IGM Biosciences to Participate in Canaccord Genuity Horizons in Oncology Virtual Event
April 03 2020 - 7:00AM
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage
biotechnology company focused on creating and developing engineered
IgM antibodies, today announced that Fred Schwarzer, Chief
Executive Officer, will participate in a panel discussion on
bispecific therapies at the Canaccord Genuity Horizons in Oncology
Virtual Event on Wednesday, April 8 at 10:15 a.m. ET.
A live webcast of the event will be available on the “Events and
Presentations” page in the “Investors” section of the Company’s
website at
https://investor.igmbio.com/news-and-events/events-and-presentations.
A replay of the webcast will be archived on the Company’s website
for 90 days following the presentation.
About IGM Biosciences, Inc. Headquartered in
Mountain View, California, IGM Biosciences is a clinical-stage
biotechnology company focused on creating and developing engineered
IgM antibodies. Since 2010, IGM Biosciences has worked to overcome
the manufacturing and protein engineering hurdles that have limited
the therapeutic use of IgM antibodies. Through its efforts, IGM
Biosciences has created a proprietary IgM technology platform for
the development of IgM antibodies for those clinical indications
where their inherent properties may provide advantages as compared
to IgG antibodies.
Contact:
Argot Partners David Pitts212-600-1902
igmbio@argotpartners.com
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Jul 2023 to Jul 2024